Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD), a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones, reported its financial results for the quarter ended March 31, 2014. Galmed reported a positive cash flow from financing activities of $41.9 million for the quarter ended March 31, 2014 as compared to a negative cash flow from financing activities of $20,000 for the quarter ended March 31, 2013. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) weekly performance is -2.33%. On last trading day company shares ended up $6.71. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) distance from 50-day simple moving average (SMA50) is -33.56%.
Stock analysts at MLV & Co cut their price objective on shares of Acura Pharmaceuticals (NASDAQ:ACUR) from $2.25 to $2.00 in a report issued on Friday, American Banking and Market News reports. MLV & Co ‘s price target indicates a potential upside of 62.60% from the stock’s previous close. Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) shares fell -5.04% in last trading session and ended the day on $1.13. ACUR return on assets is -57.30%.Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) quarterly performance is -35.80%.
MEI Pharma, Inc. (NASDAQ:MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that Daniel P. Gold, Ph.D., President and Chief Executive Officer, will present at The UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 9:00 a.m. Eastern time from the Sheraton New York Times Square Hotel. MEI Pharma Inc. (NASDAQ:MEIP) shares moved down -2.80% in last trading session and was closed at $6.25, while trading in range of $6.11 – $6.83. MEI Pharma Inc. (NASDAQ:MEIP) year to date (YTD) performance is -21.97%.
Trovagene, Inc. (NASDAQ:TROV), a developer of cell-free molecular diagnostics, announced that data from a study of its precision cancer monitoring technology, conducted by MD Anderson Cancer Center and Memorial Sloan-Kettering Cancer Center, will be presented during a poster session at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). TrovaGene Inc. (NASDAQ:TROV) ended the last trading day at $4.08. Company weekly volatility is calculated as 11.13% and price to cash ratio as 2.99.TrovaGene Inc. (NASDAQ:TROV) showed a negative weekly performance of -14.82%.